June 2014, Vol 5, No 5

Los Angeles, CA—Although targeted drug development and testing are clearly transforming medicine, resistance to greater uptake of personalized medicine includes a shift in the evidence threshold in personalized testing and drawbacks to the delivery system, including the cost of molecular tests, said Peter B. Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, at the Fourth Annual Conference of the Association for Value-Based Cancer Care.

Los Angeles, CA—An agenda for personalized medicine must address quality control for test performance, billing and coding for molecular tests, and other practical challenges.